The battle for supremacy in the weight-loss drug market is shifting decisively from the injectable era to a new oral frontier. Late last year, regulators approved the first oral GLP-1 treatment for obesity, and analysts forecast the total market will approach $100 billion by 2030. Seated at the table are the same two heavyweights: Danish pharmaceutical giant Novo Nordisk (NVO) and American juggernaut Eli Lilly (LLY) .
During the injectable phase, Eli Lilly pulled off a stunning reversal. Armed with superior efficacy data for tirzepatide (sold as Mounjaro for diabetes and Zepbound for weight loss) and an aggressive manufacturing scale-up, Lilly seized a commanding 60% share of the U.S. market. But now the playing field has leveled out with pills. Can Novo Nordisk reclaim the initiative with its first-mover advantage in oral drugs? Or will Lilly’s newly approved pill, Foundayo , follow the same script of disruption?
Novo Nordisk’s strength lies in its head start. Semaglutide has been on the market since 2017 under the Ozempic brand, and the oral version of Wegovy secured approval late last year, making it the first oral GLP-1 option available for weight management.
The company’s staying power hinges on user conversion. A significant barrier to injectables has always been patient compliance—many people simply dislike needles. The oral formulation unlocks a previously untapped demographic. Data from Truveta shows that more than 36% of oral Wegovy users are new to the GLP-1 drug class. This is a critical metric; it suggests the pill is expanding the overall pie rather than just siphoning patients away from Novo Nordisk’s own injectable franchise. As Novo ramps up production capacity for the oral tablet, this pent-up demand is poised to translate directly into fresh revenue streams.
Eli Lilly’s counterpunch is Foundayo, and its core selling point is convenience.
Existing oral semaglutide comes with a notable drawback: it must be taken on an empty stomach, with a strict 30-minute waiting period before consuming any food or drink. For patients with busy or irregular schedules, this is a genuine compliance hurdle. In contrast, clinical data for Foundayo indicates it can be taken with or without food and beverages. In the long-term management of a chronic condition, this seemingly small distinction creates a significant divide in patient adherence.
Furthermore, Lilly carries a potent “efficacy halo” from the injectable arena. While direct head-to-head data between the oral pills is still pending, the established narrative—backed by previous studies—is that tirzepatide delivers greater weight loss than semaglutide. This perception of superior performance is deeply embedded in the prescribing habits of physicians and the expectations of patients. Entering the oral race with this reputational advantage gives Lilly an immediate and substantial premium in the eyes of the market.
The financials lay bare the current dynamic. Mounjaro and Zepbound alone generated over $36 billion in revenue for Eli Lilly last year. While Novo Nordisk remains a formidable financial force, its growth trajectory in the key U.S. market has visibly flattened relative to its rival.
This divergence is starkly reflected in market valuations:
Looking ahead over the next three years, Eli Lilly appears to have the greater stamina.
Novo Nordisk’s growth thesis now rests on a narrow premise: it must successfully defend its oral beachhead and prevent a sharp decline in its injectable business. If Foundayo capitalizes on its convenience advantage and begins chipping away at market share—just as injectable tirzepatide did—Novo Nordisk faces the prospect of both an earnings slowdown and multiple contraction.
Eli Lilly’s position, however, offers a much wider margin of error. Tirzepatide injections are already a reliable cash cow. Foundayo is, for the moment, a call option on future growth. If the new pill underperforms, Lilly’s 60% injectable share remains a solid foundation. But if Foundayo’s convenience translates into a market share grab, the revenue ceiling for Lilly gets raised substantially higher.
As analyst Adria Cimino noted, expecting Lilly’s stock to become a standalone ten-bagger at its current valuation is unrealistic. However, when constructing a long-term portfolio, selecting the company with a higher margin of error and stronger competitive positioning is almost always the safer bet. In the marathon of the oral weight-loss market, Eli Lilly has settled into the more comfortable pace.
